ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

DCCP Recompetitions Approved Board Asks Others At NIH To Help Pay For Some Resources

October 24, 1980

NCI CTEP-Approved Trials For the Month of July

July 25, 2014

MSKCC oncologist settles insider trading case with SEC.

November 11, 2005

Natcher Subcommittee Objects To Budget Reductions, Squeeze From DeVita Details On Programs Being Cut

March 15, 1985

Contract For NCI CIS Service Center Awarded To Fred Hutchinson

December 11, 2009

CCOP Summary Statements Soon To Be Available

April 22, 1983